Person · CIK 1235945

Wendall Wierenga

Director at Cytokinetics and Crinetics Pharmaceuticals

Earlier: Concert Pharmaceuticals, Apricus Biosciences, Ocera Therapeutics, Xenoport, Anacor Pharmaceuticals, Santarus, Onyx Pharmaceuticals and Neurocrine Biosciences

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$5.9M

Noticed on Form 144$2M

Bought on Form 4$117K

Companies10

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Cytokinetics CYTK	Common Stock	Directly	32,345	Jul 15, 2025 · Filing · EDGAR
Cytokinetics CYTK	Non-Qualified Stock Option (Right to Buy) exercise $30.00, expires May 13, 2035, into Common Stock	Directly	10,880	May 14, 2025 · Filing · EDGAR
Crinetics Pharmaceuticals CRNX	Common Stock	Directly	116,146	Jun 11, 2025 · Filing · EDGAR
Crinetics Pharmaceuticals CRNX	Stock Option (right to buy) exercise $32.33, expires Jun 11, 2035, into Common Stock	Directly	10,350	Jun 11, 2025 · Filing · EDGAR
Concert Pharmaceuticals	Common Stock	Directly	12,389	Mar 13, 2014 · Filing · EDGAR
Concert Pharmaceuticals	Nonstatutory Stock Option (Right to Buy) exercise $19.59, expires Jun 13, 2028, into Common Stock	Directly	10,000	Jun 14, 2018 · Filing · EDGAR
Apricus Biosciences	Common Stock	Directly	20,000	Oct 22, 2014 · Filing · EDGAR
Apricus Biosciences	Common Stock	Wierenga Family Trust	15,373	Jan 5, 2017 · Filing · EDGAR
Apricus Biosciences	Stock Option (right to buy) exercise $2.11, expires Jan 4, 2028, into Common Stock	Directly	35,000	Jan 4, 2018 · Filing · EDGAR
Neurocrine Biosciences	Common Stock	Directly	5,023	Oct 10, 2003 · Filing · EDGAR
Neurocrine Biosciences	Restricted Stock Units into Common Stock	Directly	5,000	Jan 19, 2006 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)	Bought (Form 4)
Q2 2025	$769K	$769K	—
Q4 2024	$306K	$306K	—
Q4 2023	$736K	$736K	—
Q3 2023	$193K	$193K	—
Q1 2023	$315K	Not machine-readable	—
Q3 2022	$220K	Not machine-readable	—
Q4 2021	$185K	Not machine-readable	—
Q2 2020	$160K	Not machine-readable	—
Q2 2015	—	—	$47K
Q4 2014	—	—	$30K
Q2 2014	—	—	$40K
Q1 2013	$19K	Not machine-readable	—
Q4 2012	$19K	Not machine-readable	—
Q3 2012	$389K	Not machine-readable	—
Q2 2012	$11K	Not machine-readable	—
Q1 2012	$10K	Not machine-readable	—
Q4 2011	$10K	Not machine-readable	—
Q3 2011	$8K	Not machine-readable	—
Q2 2011	$9K	Not machine-readable	—
Q3 2008	$399K	Not machine-readable	—
Q4 2007	$164K	Not machine-readable	—
Q3 2007	$447K	Not machine-readable	—
Q2 2007	$206K	Not machine-readable	—
Q1 2007	$196K	Not machine-readable	—
Q4 2006	$220K	Not machine-readable	—
Q1 2004	$110K	Not machine-readable	—
Q4 2003	$833K	Not machine-readable	—

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Cytokinetics CYTK · Morgan Stanley Smith Barney · 10b5-1 plan adopted Mar 4, 2024 · 4 notices
Apr 21, 2025	20,000 · ~$769K	Apr 21, 2025	Sold as noticed Sold 20,000 at $38.46 on Apr 21 · $769K Form 4	Filing · EDGAR
Dec 16, 2024	742 · ~$36K	Dec 16, 2024	Sold as noticed Sold 742 at $48.61 on Dec 16 · $36K Form 4	Filing · EDGAR
Nov 25, 2024	742 · ~$37K	Nov 25, 2024	Sold as noticed Sold 742 at $50.00 on Nov 25 · $37K Form 4	Filing · EDGAR
Oct 28, 2024	4,452 · ~$233K	Oct 28, 2024	Sold as noticed Sold 4,452 at $52.25 on Oct 28 · $233K Form 4	Filing · EDGAR
Cytokinetics CYTK · Morgan Stanley Smith Barney · 10b5-1 plan adopted Sep 7, 2023 · 1 notice
Dec 27, 2023	10,000 · ~$736K	Dec 27, 2023	Sold as noticed Sold 10,000 in 2 sales, Dec 27 to Dec 27 · $736K Form 4	Filing · EDGAR
Cytokinetics CYTK · E*Trade Financial · 10b5-1 plan adopted Mar 9, 2023 · 1 notice
Aug 21, 2023	6,020 · ~$193K	Aug 21, 2023	Sold as noticed Sold 6,020 at $32.02 on Aug 21 · $193K Form 4	Filing · EDGAR
Sales without a matching Form 144 · 77 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Notice not machine-readable Cytokinetics (CYTK): Sold 7,000 at $45.00 on Feb 6, 2023 · $315K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Cytokinetics (CYTK): Sold 4,166 at $52.79 on Sep 1, 2022 · $220K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Cytokinetics (CYTK): Sold 4,166 at $44.37 on Dec 27, 2021 · $185K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Cytokinetics (CYTK): Sold 6,666 at $16.00 on Apr 28, 2020 · $107K	Filing · EDGAR
—	—	—	Notice not machine-readable Cytokinetics (CYTK): Sold 3,333 at $16.00 on Apr 28, 2020 · $53K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 250 at $77.71 on Feb 1, 2013 · $19K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 250 at $77.21 on Nov 1, 2012 · $19K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 5,000 at $74.09 on Aug 24, 2012 · $370K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 250 at $74.76 on Aug 1, 2012 · $19K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 250 at $45.47 on May 1, 2012 · $11K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 250 at $41.38 on Feb 1, 2012 · $10K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 250 at $39.37 on Nov 1, 2011 · $10K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 250 at $33.27 on Aug 1, 2011 · $8K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 250 at $37.67 on May 2, 2011 · $9K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 1,500 at $41.04 on Aug 27, 2008 · $62K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 1,500 at $41.00 on Aug 27, 2008 · $62K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 2,000 at $40.98 on Aug 27, 2008 · $82K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 100 at $48.68 on Aug 19, 2008 · $5K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 200 at $48.61 on Aug 19, 2008 · $10K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 100 at $48.58 on Aug 19, 2008 · $5K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 300 at $48.57 on Aug 19, 2008 · $15K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 600 at $48.55 on Aug 19, 2008 · $29K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 200 at $48.55 on Aug 19, 2008 · $10K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 200 at $48.55 on Aug 19, 2008 · $10K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 1,200 at $48.53 on Aug 19, 2008 · $58K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 100 at $48.53 on Aug 19, 2008 · $5K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 200 at $48.52 on Aug 19, 2008 · $10K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 100 at $48.51 on Aug 19, 2008 · $5K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 200 at $48.51 on Aug 19, 2008 · $10K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 200 at $48.51 on Aug 19, 2008 · $10K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 300 at $48.50 on Aug 19, 2008 · $15K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 656 at $55.15 on Dec 5, 2007 · $36K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 200 at $55.00 on Dec 5, 2007 · $11K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 126 at $54.80 on Dec 5, 2007 · $7K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 700 at $54.79 on Dec 5, 2007 · $38K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 1,318 at $54.50 on Dec 5, 2007 · $72K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 300 at $38.90 on Aug 30, 2007 · $12K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 300 at $38.92 on Aug 30, 2007 · $12K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 900 at $38.91 on Aug 30, 2007 · $35K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 400 at $38.89 on Aug 30, 2007 · $16K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 200 at $38.84 on Aug 30, 2007 · $8K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 900 at $38.88 on Aug 30, 2007 · $35K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 2,300 at $38.82 on Aug 30, 2007 · $89K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 1,500 at $38.85 on Aug 30, 2007 · $58K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 4,700 at $38.86 on Aug 30, 2007 · $183K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 5,000 at $41.15 on May 16, 2007 · $206K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 500 at $28.04 on Feb 22, 2007 · $14K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 1,000 at $28.05 on Feb 22, 2007 · $28K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 5,000 at $28.02 on Feb 22, 2007 · $140K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 500 at $27.98 on Feb 22, 2007 · $14K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 4,000 at $25.02 on Dec 15, 2006 · $100K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 1,200 at $23.94 on Nov 6, 2006 · $29K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 100 at $23.92 on Nov 6, 2006 · $2K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 300 at $23.91 on Nov 6, 2006 · $7K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 3,300 at $23.90 on Nov 6, 2006 · $79K	Filing · EDGAR
—	—	—	Notice not machine-readable Xenoport: Sold 100 at $23.87 on Nov 6, 2006 · $2K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 1,189 at $36.47 on Mar 23, 2004 · $43K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 399 at $36.49 on Mar 23, 2004 · $15K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 100 at $36.50 on Mar 23, 2004 · $4K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 194 at $36.52 on Mar 23, 2004 · $7K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 425 at $36.59 on Mar 23, 2004 · $16K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 693 at $36.64 on Mar 23, 2004 · $25K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 5,462 at $24.12 on Nov 4, 2003 · $132K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 1,000 at $24.13 on Nov 4, 2003 · $24K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 200 at $24.14 on Nov 4, 2003 · $5K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 4,458 at $24.15 on Nov 4, 2003 · $108K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 400 at $24.17 on Nov 4, 2003 · $10K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 728 at $24.18 on Nov 4, 2003 · $18K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 172 at $24.19 on Nov 4, 2003 · $4K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 100 at $24.26 on Nov 4, 2003 · $2K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 5,780 at $24.12 on Nov 3, 2003 · $139K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 1,500 at $24.13 on Nov 3, 2003 · $36K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 3,900 at $24.14 on Nov 3, 2003 · $94K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 2,800 at $24.15 on Nov 3, 2003 · $68K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 2,300 at $24.16 on Nov 3, 2003 · $56K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 800 at $24.17 on Nov 3, 2003 · $19K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 4,900 at $24.20 on Nov 3, 2003 · $119K	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Cytokinetics CYTK Director · filings 2011 to 2025 · sold $2.9M · $2M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jul 15, 2025	Grant or award from the company	+164	$38.01	$6K	32,345 direct	Filing · EDGAR
May 14, 2025	Grant or award from the company	+7,333			32,181 direct	Filing · EDGAR
May 14, 2025	Grant or award from the company Non-Qualified Stock Option (Right to Buy)	+10,880			10,880 direct	Filing · EDGAR
Apr 21, 2025	Option or RSU exercised or converted	+20,000	$6.21	$124K	44,848 direct	Filing · EDGAR
Apr 21, 2025	Sale under a 10b5-1 plan	−20,000	$38.46	$769K	24,848 direct	Filing · EDGAR
Apr 21, 2025	Option or RSU exercised or converted Stock Option (Right to Buy)	−20,000			0 direct	Filing · EDGAR
Apr 15, 2025	Grant or award from the company	+162	$38.56	$6K	24,848 direct	Filing · EDGAR
Jan 2, 2025	Grant or award from the company	+127	$48.93	$6K	24,686 direct	Filing · EDGAR
Dec 16, 2024	Option or RSU exercised or converted	+742	$7.37	$5K	25,301 direct	Filing · EDGAR
Dec 16, 2024	Sale under a 10b5-1 plan	−742	$48.61	$36K	24,559 direct	Filing · EDGAR
Dec 16, 2024	Option or RSU exercised or converted Non-Qualified Stock Option (Right to Buy)	−742			0 direct	Filing · EDGAR
Nov 25, 2024	Option or RSU exercised or converted	+742	$7.37	$5K	25,301 direct	Filing · EDGAR
Nov 25, 2024	Sale under a 10b5-1 plan	−742	$50.00	$37K	24,559 direct	Filing · EDGAR
Nov 25, 2024	Option or RSU exercised or converted Non-Qualified Stock Option (Right to Buy)	−742			742 direct	Filing · EDGAR
Oct 28, 2024	Option or RSU exercised or converted	+4,452	$7.37	$33K	29,011 direct	Filing · EDGAR
Oct 28, 2024	Sale under a 10b5-1 plan	−4,452	$52.25	$233K	24,559 direct	Filing · EDGAR
Oct 28, 2024	Option or RSU exercised or converted Non-Qualified Stock Option (Right to Buy)	−4,452			1,484 direct	Filing · EDGAR
Oct 1, 2024	Grant or award from the company	+118	$52.60	$6K	24,559 direct	Filing · EDGAR
Jul 1, 2024	Grant or award from the company	+114			24,441 direct	Filing · EDGAR
May 15, 2024	Grant or award from the company	+5,600			24,327 direct	Filing · EDGAR
May 15, 2024	Grant or award from the company Non-Qualified Stock Option (Right to Buy)	+3,636			3,636 direct	Filing · EDGAR
Jan 2, 2024	Grant or award from the company	+74	$84.12	$6K	18,727 direct	Filing · EDGAR
Dec 27, 2023	Option or RSU exercised or converted	+5,000	$4.44	$22K	23,653 direct	Filing · EDGAR
Dec 27, 2023	Sale under a 10b5-1 plan	−5,000	$73.60	$368K	18,653 direct	Filing · EDGAR
Dec 27, 2023	Option or RSU exercised or converted	+5,000	$4.44	$22K	23,653 direct	Filing · EDGAR
Dec 27, 2023	Sale under a 10b5-1 plan	−5,000	$73.60	$368K	18,653 direct	Filing · EDGAR
Dec 27, 2023	Option or RSU exercised or converted Non-Qualified Stock Option (Right to Buy)	−5,000			5,000 direct	Filing · EDGAR
Dec 27, 2023	Option or RSU exercised or converted Non-Qualified Stock Option (Right to Buy)	−5,000			0 direct	Filing · EDGAR
Oct 2, 2023	Grant or award from the company	+448	$27.88	$12K	18,653 direct	Filing · EDGAR
Aug 21, 2023	Option or RSU exercised or converted	+6,020	$6.72	$40K	24,225 direct	Filing · EDGAR
Aug 21, 2023	Sale under a 10b5-1 plan	−6,020	$32.02	$193K	18,205 direct	Filing · EDGAR
Aug 21, 2023	Option or RSU exercised or converted Non-Qualified Stock Option (Right to Buy)	−6,020			0 direct	Filing · EDGAR
Jul 3, 2023	Grant or award from the company	+374	$33.36	$12K	18,205 direct	Filing · EDGAR
May 10, 2023	Grant or award from the company	+5,000			17,831 direct	Filing · EDGAR
May 10, 2023	Grant or award from the company Non-Qualified Stock Option (Right to Buy)	+10,000			10,000 direct	Filing · EDGAR
Apr 3, 2023	Grant or award from the company	+298	$37.71	$11K	12,831 direct	Filing · EDGAR
Feb 6, 2023	Option or RSU exercised or converted	+7,000	$6.72	$47K	19,533 direct	Filing · EDGAR
Feb 6, 2023	Sale under a 10b5-1 plan	−7,000	$45.00	$315K	12,533 direct	Filing · EDGAR
Feb 6, 2023	Option or RSU exercised or converted Non-Qualified Stock Option (Right to Buy)	−7,000			6,020 direct	Filing · EDGAR
Jan 3, 2023	Grant or award from the company	+253	$44.35	$11K	12,533 direct	Filing · EDGAR
Oct 3, 2022	Grant or award from the company	+110	$51.11	$6K	12,280 direct	Filing · EDGAR
Sep 1, 2022	Option or RSU exercised or converted	+4,166	$6.78	$28K	16,336 direct	Filing · EDGAR
Sep 1, 2022	Sale under a 10b5-1 plan	−4,166	$52.79	$220K	12,170 direct	Filing · EDGAR
Sep 1, 2022	Option or RSU exercised or converted Non-Qualified Stock Option (Right to Buy)	−4,166			0 direct	Filing · EDGAR
Jul 1, 2022	Grant or award from the company	+137	$41.00	$6K	12,170 direct	Filing · EDGAR
May 10, 2022	Grant or award from the company	+5,000			12,033 direct	Filing · EDGAR
May 10, 2022	Grant or award from the company Non-Qualified Stock Option (right to buy)	+10,000			10,000 direct	Filing · EDGAR
Apr 1, 2022	Grant or award from the company	+146	$38.38	$6K	7,033 direct	Filing · EDGAR
Jan 3, 2022	Grant or award from the company	+122	$46.00	$6K	6,887 direct	Filing · EDGAR
Dec 27, 2021	Option or RSU exercised or converted	+4,166	$5.46	$23K	10,931 direct	Filing · EDGAR
Dec 27, 2021	Sale under a 10b5-1 plan	−4,166	$44.37	$185K	6,765 direct	Filing · EDGAR
Dec 27, 2021	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−4,166			0 direct	Filing · EDGAR
Oct 1, 2021	Grant or award from the company	+306	$36.74	$11K	6,765 direct	Filing · EDGAR
Jul 7, 2021	Grant or award from the company	+63	$19.77	$1K	6,459 direct	Filing · EDGAR
Jul 1, 2021	Grant or award from the company	+476	$20.98	$10K	6,396 direct	Filing · EDGAR
May 12, 2021	Grant or award from the company	+5,000			5,920 direct	Filing · EDGAR
May 12, 2021	Grant or award from the company Non-Qualified Stock Option (right to buy)	+10,000			10,000 direct	Filing · EDGAR
Apr 1, 2021	Grant or award from the company	+409	$24.44	$10K	920 direct	Filing · EDGAR
Jan 4, 2021	Grant or award from the company	+511	$19.56	$10K	511 direct	Filing · EDGAR
May 13, 2020	Grant or award from the company Non-Qualified Stock Option (right to buy)	+20,000	$21.61	$432K	20,000 direct	Filing · EDGAR

21 earlier transactions are in the filing list below.

Crinetics Pharmaceuticals CRNX Director · filings 2018 to 2025

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 11, 2025	Grant or award from the company	+6,900			116,146 direct	Filing · EDGAR
Jun 11, 2025	Grant or award from the company Stock Option (right to buy)	+10,350			10,350 direct	Filing · EDGAR
Jun 7, 2024	Grant or award from the company	+3,400			109,246 direct	Filing · EDGAR
Jun 7, 2024	Grant or award from the company Stock Option (right to buy)	+12,500			12,500 direct	Filing · EDGAR
Jun 16, 2023	Grant or award from the company	+6,000			105,846 direct	Filing · EDGAR
Jun 16, 2023	Grant or award from the company Stock Option (right to buy)	+17,500			17,500 direct	Filing · EDGAR
Jun 17, 2022	Grant or award from the company Stock Option (right to buy)	+17,500			17,500 direct	Filing · EDGAR
Jun 22, 2021	Grant or award from the company Stock Option (right to buy)	+17,500			17,500 direct	Filing · EDGAR
Jun 19, 2020	Grant or award from the company Stock Option (right to buy)	+12,500			12,500 direct	Filing · EDGAR
Apr 28, 2020	Option or RSU exercised or converted	+25,329	$0.73	$18K	99,846 direct	Filing · EDGAR
Apr 28, 2020	Option or RSU exercised or converted Stock Option (right to but)	−25,329			12,500 direct	Filing · EDGAR
Jun 21, 2019	Grant or award from the company Stock Option (right to buy)	+12,500			12,500 direct	Filing · EDGAR

Concert Pharmaceuticals Director · filings 2014 to 2018

Date	Transaction	Shares	Held after	Source
Jun 14, 2018	Grant or award from the company Nonstatutory Stock Option (Right to Buy)	+10,000	10,000 direct	Filing · EDGAR
Jun 15, 2017	Grant or award from the company Nonstatutory Stock Option (right to buy)	+10,000	10,000 direct	Filing · EDGAR
Jun 9, 2016	Grant or award from the company Nonstatutory Stock Option (right to buy)	+10,000	10,000 direct	Filing · EDGAR
Jun 11, 2015	Grant or award from the company Nonstatutory Stock Option (right to buy)	+10,000	10,000 direct	Filing · EDGAR
Mar 13, 2014	Grant or award from the company Employee Stock Option (right to buy)	+25,000	25,000 direct	Filing · EDGAR

Apricus Biosciences Director · filings 2014 to 2018 · bought $30K

Date	Transaction	Shares	Price	Value	Held after	Source
Jan 4, 2018	Grant or award from the company Stock Option (right to buy)	+35,000			35,000 direct	Filing · EDGAR
Jan 5, 2017	Grant or award from the company	+11,250			15,373 Wierenga Family Trust	Filing · EDGAR
Sep 30, 2016	Grant or award from the company	+8,868	$0.34	$3K	41,228 Wierenga Family Trust	Filing · EDGAR
Jun 30, 2016	Grant or award from the company	+7,510	$0.40	$3K	32,360 Wierenga Family Trust	Filing · EDGAR
Apr 5, 2016	Grant or award from the company	+4,850	$0.58	$3K	24,850 Wierenga Family Trust	Filing · EDGAR
Jan 4, 2016	Grant or award from the company Stock Option (right to buy)	+25,000			25,000 direct	Filing · EDGAR
Jan 2, 2015	Grant or award from the company Stock Option (right to buy)	+25,000			25,000 direct	Filing · EDGAR
Oct 22, 2014	Open-market or private purchase	+20,000	$1.52	$30K	20,000 direct	Filing · EDGAR
Mar 10, 2014	Grant or award from the company Stock Option (right to buy)	+100,000			100,000 direct	Filing · EDGAR

Ocera Therapeutics Director · filings 2013 to 2017 · bought $19K

Date	Transaction	Shares	Price	Value	Held after	Source
Dec 11, 2017	Returned to the company	−5,000	$1.52	$8K	0 direct	Filing · EDGAR
Dec 11, 2017	Returned to the company	−12,500	$1.52	$19K	0 direct	Filing · EDGAR
Dec 11, 2017	Returned to the company Stock Option (Right to Buy)	−20,000			0 direct	Filing · EDGAR
Dec 11, 2017	Returned to the company Stock Option (Right to Buy)	−10,000			0 direct	Filing · EDGAR
Dec 11, 2017	Returned to the company Stock Option (Right to Buy)	−10,000			0 direct	Filing · EDGAR
Dec 11, 2017	Returned to the company Stock Option (Right to Buy)	−12,500			0 direct	Filing · EDGAR
Jun 20, 2017	Grant or award from the company	+12,500			17,500 direct	Filing · EDGAR
Jun 14, 2016	Grant or award from the company Stock Option (Right to Buy)	+12,500			12,500 direct	Filing · EDGAR
Jun 23, 2015	Open-market or private purchase	+5,000	$3.71	$19K	5,000 direct	Filing · EDGAR
Jun 18, 2015	Grant or award from the company Stock Option (Right to Buy)	+10,000			10,000 direct	Filing · EDGAR
Jun 11, 2014	Grant or award from the company Stock Option (Right to Buy)	+10,000			10,000 direct	Filing · EDGAR
Dec 19, 2013	Grant or award from the company Stock Option (Right to Buy)	+20,000			20,000 direct	Filing · EDGAR

Xenoport Director · filings 2005 to 2016 · sold $784K · bought $68K

Date	Transaction	Shares	Price	Value	Held after	Source
Jul 5, 2016	Tendered in a change of control	−38,998	$7.03	$274K	0 direct	Filing · EDGAR
Jul 5, 2016	Returned to the company Stock Options	−15,000	$7.03	$105K	0 direct	Filing · EDGAR
Jul 5, 2016	Returned to the company Stock Options	−15,000	$7.03	$105K	0 direct	Filing · EDGAR
Jul 5, 2016	Returned to the company Stock Options	−15,000	$7.03	$105K	0 direct	Filing · EDGAR
Jul 5, 2016	Returned to the company Stock Options	−15,000	$7.03	$105K	0 direct	Filing · EDGAR
Jul 5, 2016	Returned to the company Stock Options	−15,000	$7.03	$105K	0 direct	Filing · EDGAR
Jul 5, 2016	Returned to the company Restricted Stock Units	−5,000	$7.03	$35K	0 direct	Filing · EDGAR
May 17, 2016	Option or RSU exercised or converted	+5,000			38,998 direct	Filing · EDGAR
May 17, 2016	Option or RSU exercised or converted Non-Employee Restricted Stock Units	−5,000			0 direct	Filing · EDGAR
May 17, 2016	Grant or award from the company Non-Employee Stock Options	+15,000			15,000 direct	Filing · EDGAR
May 17, 2016	Grant or award from the company Non-Employee Restricted Stock Units	+5,000			5,000 direct	Filing · EDGAR
May 19, 2015	Option or RSU exercised or converted	+5,000			33,998 direct	Filing · EDGAR
May 19, 2015	Option or RSU exercised or converted Non-Employee Restricted Stock Units	−5,000			0 direct	Filing · EDGAR
May 19, 2015	Grant or award from the company Non-Employee Stock Options	+15,000			15,000 direct	Filing · EDGAR
May 19, 2015	Grant or award from the company Non-Employee Restricted Stock Units	+5,000			5,000 direct	Filing · EDGAR
May 11, 2015	Open-market or private purchase	+5,000	$5.63	$28K	28,998 direct	Filing · EDGAR
Jun 17, 2014	Grant or award from the company Non-employee director stock unit	+5,000			5,000 direct	Filing · EDGAR
Jun 11, 2014	Grant or award from the company Non-employee director stock option	+15,000			15,000 direct	Filing · EDGAR
May 27, 2014	Open-market or private purchase	+10,000	$3.99	$40K	23,998 direct	Filing · EDGAR
May 14, 2014	Option or RSU exercised or converted	+5,000			13,998 direct	Filing · EDGAR
May 14, 2014	Option or RSU exercised or converted Non-employee director stock unit	−5,000			0 direct	Filing · EDGAR
May 16, 2013	Option or RSU exercised or converted	+5,000			8,998 direct	Filing · EDGAR
May 16, 2013	Option or RSU exercised or converted Non-employee director stock unit	+5,000			0 direct	Filing · EDGAR
May 14, 2013	Grant or award from the company Non-employee director stock option	+15,000			15,000 direct	Filing · EDGAR
May 14, 2013	Grant or award from the company Non-employee director stock unit	+5,000			5,000 direct	Filing · EDGAR
May 16, 2012	Grant or award from the company Non-employee director stock option	+15,000			15,000 direct	Filing · EDGAR
May 16, 2012	Grant or award from the company Non-employee director stock unit	+5,000			5,000 direct	Filing · EDGAR
May 11, 2011	Grant or award from the company Non-employee director stock option	+10,000			10,000 direct	Filing · EDGAR
May 11, 2010	Grant or award from the company Non-employee director stock option	+10,000			10,000 direct	Filing · EDGAR
May 7, 2009	Grant or award from the company Non-employee director stock option	+10,000			10,000 direct	Filing · EDGAR
Aug 19, 2008	Open-market or private sale	−300	$48.50	$15K	7,698 direct	Filing · EDGAR
Aug 19, 2008	Open-market or private sale	−200	$48.51	$10K	7,498 direct	Filing · EDGAR
Aug 19, 2008	Open-market or private sale	−200	$48.51	$10K	7,298 direct	Filing · EDGAR
Aug 19, 2008	Open-market or private sale	−100	$48.51	$5K	7,198 direct	Filing · EDGAR
Aug 19, 2008	Open-market or private sale	−200	$48.52	$10K	6,998 direct	Filing · EDGAR
Aug 19, 2008	Open-market or private sale	−100	$48.53	$5K	6,898 direct	Filing · EDGAR
Aug 19, 2008	Open-market or private sale	−1,200	$48.53	$58K	5,698 direct	Filing · EDGAR
Aug 19, 2008	Open-market or private sale	−200	$48.55	$10K	5,498 direct	Filing · EDGAR
Aug 19, 2008	Open-market or private sale	−200	$48.55	$10K	5,298 direct	Filing · EDGAR
Aug 19, 2008	Open-market or private sale	−600	$48.55	$29K	4,698 direct	Filing · EDGAR
Aug 19, 2008	Open-market or private sale	−300	$48.57	$15K	4,398 direct	Filing · EDGAR
Aug 19, 2008	Open-market or private sale	−100	$48.58	$5K	4,298 direct	Filing · EDGAR
Aug 19, 2008	Open-market or private sale	−200	$48.61	$10K	4,098 direct	Filing · EDGAR
Aug 19, 2008	Open-market or private sale	−100	$48.68	$5K	3,998 direct	Filing · EDGAR
May 8, 2008	Grant or award from the company Non-employee director stock option	+10,000			10,000 direct	Filing · EDGAR
Dec 5, 2007	Open-market or private sale	−1,318	$54.50	$72K	9,680 direct	Filing · EDGAR
Dec 5, 2007	Open-market or private sale	−700	$54.79	$38K	8,980 direct	Filing · EDGAR
Dec 5, 2007	Open-market or private sale	−126	$54.80	$7K	8,854 direct	Filing · EDGAR
Dec 5, 2007	Open-market or private sale	−200	$55.00	$11K	8,654 direct	Filing · EDGAR
Dec 5, 2007	Open-market or private sale	−656	$55.15	$36K	7,998 direct	Filing · EDGAR
May 30, 2007	Grant or award from the company Non-employee director stock option	+10,000			10,000 direct	Filing · EDGAR
May 16, 2007	Open-market or private sale	−5,000	$41.15	$206K	10,998 direct	Filing · EDGAR
Dec 15, 2006	Open-market or private sale	−4,000	$25.02	$100K	0 Through Foundation	Filing · EDGAR
Nov 20, 2006	Gift	−4,000			15,998 direct	Filing · EDGAR
Nov 6, 2006	Open-market or private sale	−100	$23.87	$2K	24,898 direct	Filing · EDGAR
Nov 6, 2006	Open-market or private sale	−3,300	$23.90	$79K	21,598 direct	Filing · EDGAR
Nov 6, 2006	Open-market or private sale	−300	$23.91	$7K	21,298 direct	Filing · EDGAR
Nov 6, 2006	Open-market or private sale	−100	$23.92	$2K	21,198 direct	Filing · EDGAR
Nov 6, 2006	Open-market or private sale	−1,200	$23.94	$29K	19,998 direct	Filing · EDGAR
May 2, 2006	Grant or award from the company Non-employee director stock option	+10,000			10,000 direct	Filing · EDGAR

1 earlier transaction is in the filing list below.

Anacor Pharmaceuticals Director · filings 2014 to 2016

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 24, 2016	Returned to the company	−794	$99.25	$79K	0 direct	Filing · EDGAR
Jun 24, 2016	Returned to the company Stock Option (right to buy)	−27,000			0 direct	Filing · EDGAR
Jun 24, 2016	Returned to the company Stock Option (right to buy)	−4,096			0 direct	Filing · EDGAR
Jun 9, 2015	Grant or award from the company	+794			794 direct	Filing · EDGAR
Jun 9, 2015	Grant or award from the company Stock Option (right to buy)	+4,096			4,096 direct	Filing · EDGAR
Sep 11, 2014	Grant or award from the company Stock Option (right to buy)	+27,000			27,000 direct	Filing · EDGAR

Santarus EVP, r&d · filings 2011 to 2014

Date	Transaction	Shares	Price	Value	Held after	Source
Jan 2, 2014	Tendered in a change of control	−4,714	$32.00	$151K	0 direct	Filing · EDGAR
Jan 2, 2014	Returned to the company	−314	$32.00	$10K	0 direct	Filing · EDGAR
Jan 2, 2014	Returned to the company Stock Options (right to buy)	−127,500	$16.58	$2.1M	0 direct	Filing · EDGAR
Jan 2, 2014	Returned to the company Stock Options (right to buy)	−41,310	$27.07	$1.1M	0 direct	Filing · EDGAR
Jan 2, 2014	Returned to the company Stock Options (right to buy)	−200,000	$28.73	$5.7M	0 direct	Filing · EDGAR
Mar 11, 2013	Grant or award from the company Stock Options (right to buy)	+127,500			127,500 direct	Filing · EDGAR
Mar 12, 2012	Grant or award from the company Stock Options (right to buy)	+41,310			41,310 direct	Filing · EDGAR
Jul 15, 2011	Grant or award from the company Stock Options (right to buy)	+200,000			200,000 direct	Filing · EDGAR

Onyx Pharmaceuticals Director · filings 2003 to 2013 · sold $2.3M

Date	Transaction	Shares	Price	Value	Held after	Source
Oct 1, 2013	Tendered in a change of control	−9,080	$125.00	$1.1M	2,100 direct	Filing · EDGAR
Oct 1, 2013	Returned to the company	−2,100	$125.00	$263K	0 direct	Filing · EDGAR
Oct 1, 2013	Returned to the company Stock Options	−10,000			0 direct	Filing · EDGAR
Oct 1, 2013	Returned to the company Stock Options	−10,000			0 direct	Filing · EDGAR
Oct 1, 2013	Returned to the company Stock Options	−5,000			0 direct	Filing · EDGAR
Oct 1, 2013	Returned to the company Stock Options	−10,000			0 direct	Filing · EDGAR
Oct 1, 2013	Returned to the company Stock Options	−10,000			0 direct	Filing · EDGAR
Oct 1, 2013	Returned to the company Stock Options	−1,452			0 direct	Filing · EDGAR
Oct 1, 2013	Returned to the company Stock Options	−5,000			0 direct	Filing · EDGAR
Oct 1, 2013	Returned to the company Stock Options	−5,000			0 direct	Filing · EDGAR
Oct 1, 2013	Returned to the company Stock Options	−5,000			0 direct	Filing · EDGAR
Oct 1, 2013	Returned to the company Stock Options	−2,000			0 direct	Filing · EDGAR
Oct 1, 2013	Returned to the company Stock Options	−5,000			0 direct	Filing · EDGAR
Mar 28, 2013	Grant or award from the company	+2,100			11,180 direct	Filing · EDGAR
Mar 28, 2013	Grant or award from the company Stock Option (Right to Buy)	+5,900			5,900 direct	Filing · EDGAR
Feb 1, 2013	Sale under a 10b5-1 plan	−250	$77.71	$19K	9,080 direct	Filing · EDGAR
Nov 1, 2012	Sale under a 10b5-1 plan	−250	$77.21	$19K	9,330 direct	Filing · EDGAR
Aug 24, 2012	Option or RSU exercised or converted	+5,000	$27.14	$136K	14,580 direct	Filing · EDGAR
Aug 24, 2012	Open-market or private sale	−5,000	$74.09	$370K	9,580 direct	Filing · EDGAR
Aug 24, 2012	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000			0 direct	Filing · EDGAR
Aug 1, 2012	Sale under a 10b5-1 plan	−250	$74.76	$19K	9,580 direct	Filing · EDGAR
Jul 25, 2012	Grant or award from the company	+1,500			9,830 direct	Filing · EDGAR
Jul 25, 2012	Grant or award from the company Stock Option (Right to Buy)	+2,000			2,000 direct	Filing · EDGAR
May 1, 2012	Sale under a 10b5-1 plan	−250	$45.47	$11K	8,330 direct	Filing · EDGAR
Mar 30, 2012	Grant or award from the company	+3,000			8,580 direct	Filing · EDGAR
Mar 30, 2012	Grant or award from the company Stock Option (Right to Buy)	+5,000			5,000 direct	Filing · EDGAR
Feb 1, 2012	Sale under a 10b5-1 plan	−250	$41.38	$10K	5,580 direct	Filing · EDGAR
Nov 1, 2011	Sale under a 10b5-1 plan	−250	$39.37	$10K	5,830 direct	Filing · EDGAR
Aug 1, 2011	Sale under a 10b5-1 plan	−250	$33.27	$8K	6,080 direct	Filing · EDGAR
May 2, 2011	Sale under a 10b5-1 plan	−250	$37.67	$9K	6,330 direct	Filing · EDGAR
Mar 31, 2011	Grant or award from the company	+3,000			6,580 direct	Filing · EDGAR
Mar 31, 2011	Grant or award from the company Stock Option (Right to Buy)	+5,000			5,000 direct	Filing · EDGAR
May 26, 2010	Grant or award from the company	+1,000			3,580 direct	Filing · EDGAR
Mar 31, 2010	Grant or award from the company	+2,000			2,580 direct	Filing · EDGAR
Mar 31, 2010	Grant or award from the company Stock Option (Right to Buy)	+5,000			5,000 direct	Filing · EDGAR
Mar 31, 2009	Grant or award from the company	+580			580 direct	Filing · EDGAR
Mar 31, 2009	Grant or award from the company Stock Option (Right to Buy)	+1,452			1,452 direct	Filing · EDGAR
Dec 15, 2008	Grant or award from the company Stock Option (Right to Buy)	+10,000			10,000 direct	Filing · EDGAR
Aug 27, 2008	Option or RSU exercised or converted	+5,000	$11.86	$59K	5,000 direct	Filing · EDGAR
Aug 27, 2008	Open-market or private sale	−2,000	$40.98	$82K	3,000 direct	Filing · EDGAR
Aug 27, 2008	Open-market or private sale	−1,500	$41.00	$62K	1,500 direct	Filing · EDGAR
Aug 27, 2008	Open-market or private sale	−1,500	$41.04	$62K	0 direct	Filing · EDGAR
Aug 27, 2008	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000			5,000 direct	Filing · EDGAR
Dec 13, 2007	Grant or award from the company Stock Option (Right to Buy)	+10,000			10,000 direct	Filing · EDGAR
Aug 30, 2007	Option or RSU exercised or converted	+1,500	$17.50	$26K	1,500 direct	Filing · EDGAR
Aug 30, 2007	Option or RSU exercised or converted	+5,000	$15.63	$78K	6,500 direct	Filing · EDGAR
Aug 30, 2007	Option or RSU exercised or converted	+5,000	$6.66	$33K	11,500 direct	Filing · EDGAR
Aug 30, 2007	Open-market or private sale	−4,700	$38.86	$183K	6,800 direct	Filing · EDGAR
Aug 30, 2007	Open-market or private sale	−1,500	$38.85	$58K	5,300 direct	Filing · EDGAR
Aug 30, 2007	Open-market or private sale	−2,300	$38.82	$89K	3,000 direct	Filing · EDGAR
Aug 30, 2007	Open-market or private sale	−900	$38.88	$35K	2,100 direct	Filing · EDGAR
Aug 30, 2007	Open-market or private sale	−200	$38.84	$8K	1,900 direct	Filing · EDGAR
Aug 30, 2007	Open-market or private sale	−400	$38.89	$16K	1,500 direct	Filing · EDGAR
Aug 30, 2007	Open-market or private sale	−900	$38.91	$35K	600 direct	Filing · EDGAR
Aug 30, 2007	Open-market or private sale	−300	$38.92	$12K	300 direct	Filing · EDGAR
Aug 30, 2007	Open-market or private sale	−300	$38.90	$12K	0 direct	Filing · EDGAR
Aug 30, 2007	Option or RSU exercised or converted Stock Option (Right to Buy)	−1,500			0 direct	Filing · EDGAR
Aug 30, 2007	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000			0 direct	Filing · EDGAR
Aug 30, 2007	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000			0 direct	Filing · EDGAR
Feb 22, 2007	Option or RSU exercised or converted	+5,000	$5.04	$25K	5,000 direct	Filing · EDGAR

48 earlier transactions are in the filing list below.

Neurocrine Biosciences EVP, Research & Development · filings 2003 to 2006

Date	Transaction	Shares	Price	Value	Held after	Source
Jan 19, 2006	Grant or award from the company Stock Option	+20,000	$60.95	$1.2M	20,000 direct	Filing · EDGAR
Jan 19, 2006	Grant or award from the company Restricted Stock Units	+5,000			5,000 direct	Filing · EDGAR
Feb 18, 2005	Grant or award from the company Stock Option	+35,000	$40.39	$1.4M	35,000 direct	Filing · EDGAR
May 26, 2004	Grant or award from the company Stock Option	+30,000	$57.51	$1.7M	30,000 direct	Filing · EDGAR
Oct 10, 2003	Grant or award from the company	+2,023	$49.43	$100K	5,023 direct	Filing · EDGAR
Sep 1, 2003	Grant or award from the company	+3,000	$53.58	$161K	3,000 direct	Filing · EDGAR
Sep 1, 2003	Grant or award from the company Incentive Stock Option (right to buy)	+100,000	$53.58	$5.4M	100,000 direct	Filing · EDGAR

All 158 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Jul 16, 2025	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jun 13, 2025	Form 4	Crinetics Pharmaceuticals CRNX	Filing · EDGAR
May 14, 2025	Form 4	Cytokinetics CYTK	Filing · EDGAR
Apr 21, 2025	Form 144	Cytokinetics CYTK	Filing · EDGAR
Apr 21, 2025	Form 4	Cytokinetics CYTK	Filing · EDGAR
Apr 16, 2025	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jan 6, 2025	Form 4	Cytokinetics CYTK	Filing · EDGAR
Dec 16, 2024	Form 144	Cytokinetics CYTK	Filing · EDGAR
Dec 16, 2024	Form 4	Cytokinetics CYTK	Filing · EDGAR
Nov 26, 2024	Form 4	Cytokinetics CYTK	Filing · EDGAR
Nov 25, 2024	Form 144	Cytokinetics CYTK	Filing · EDGAR
Oct 31, 2024	Form 4	Cytokinetics CYTK	Filing · EDGAR
Oct 28, 2024	Form 144	Cytokinetics CYTK	Filing · EDGAR
Oct 3, 2024	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jul 3, 2024	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jun 11, 2024	Form 4	Crinetics Pharmaceuticals CRNX	Filing · EDGAR
May 16, 2024	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jan 3, 2024	Form 4	Cytokinetics CYTK	Filing · EDGAR
Dec 27, 2023	Form 144	Cytokinetics CYTK	Filing · EDGAR
Dec 27, 2023	Form 4	Cytokinetics CYTK	Filing · EDGAR
Oct 3, 2023	Form 4	Cytokinetics CYTK	Filing · EDGAR
Aug 21, 2023	Form 144	Cytokinetics CYTK	Filing · EDGAR
Aug 21, 2023	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jul 5, 2023	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jun 21, 2023	Form 4	Crinetics Pharmaceuticals CRNX	Filing · EDGAR
May 18, 2023	Form 4	Cytokinetics CYTK	Filing · EDGAR
Apr 5, 2023	Form 4	Cytokinetics CYTK	Filing · EDGAR
Feb 8, 2023	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jan 4, 2023	Form 4	Cytokinetics CYTK	Filing · EDGAR
Oct 5, 2022	Form 4	Cytokinetics CYTK	Filing · EDGAR
Sep 1, 2022	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jul 12, 2022	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jun 21, 2022	Form 4	Crinetics Pharmaceuticals CRNX	Filing · EDGAR
May 11, 2022	Form 4	Cytokinetics CYTK	Filing · EDGAR
Apr 1, 2022	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jan 4, 2022	Form 4	Cytokinetics CYTK	Filing · EDGAR
Dec 28, 2021	Form 4	Cytokinetics CYTK	Filing · EDGAR
Oct 4, 2021	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jul 8, 2021	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jul 2, 2021	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jun 23, 2021	Form 4	Crinetics Pharmaceuticals CRNX	Filing · EDGAR
May 13, 2021	Form 4	Cytokinetics CYTK	Filing · EDGAR
Apr 5, 2021	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jan 5, 2021	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jun 22, 2020	Form 4	Crinetics Pharmaceuticals CRNX	Filing · EDGAR
May 14, 2020	Form 4	Cytokinetics CYTK	Filing · EDGAR
Apr 29, 2020	Form 4	Crinetics Pharmaceuticals CRNX	Filing · EDGAR
Apr 29, 2020	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jun 25, 2019	Form 4	Crinetics Pharmaceuticals CRNX	Filing · EDGAR
May 17, 2019	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jul 17, 2018	Form 3	Crinetics Pharmaceuticals CRNX	Filing · EDGAR
Jun 18, 2018	Form 4	Concert Pharmaceuticals	Filing · EDGAR
May 17, 2018	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jan 8, 2018	Form 4	Apricus Biosciences	Filing · EDGAR
Jan 4, 2018	Form 4	Cytokinetics CYTK	Filing · EDGAR
Dec 11, 2017	Form 4	Ocera Therapeutics	Filing · EDGAR
Jun 22, 2017	Form 4	Ocera Therapeutics	Filing · EDGAR
Jun 19, 2017	Form 4	Concert Pharmaceuticals	Filing · EDGAR
May 22, 2017	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jan 6, 2017	Form 4	Apricus Biosciences	Filing · EDGAR
Jan 4, 2017	Form 4	Cytokinetics CYTK	Filing · EDGAR
Oct 3, 2016	Form 4	Apricus Biosciences	Filing · EDGAR
Jul 6, 2016	Form 4	Xenoport	Filing · EDGAR
Jul 1, 2016	Form 4	Apricus Biosciences	Filing · EDGAR
Jun 24, 2016	Form 4	Anacor Pharmaceuticals	Filing · EDGAR
Jun 15, 2016	Form 4	Ocera Therapeutics	Filing · EDGAR
Jun 10, 2016	Form 4	Concert Pharmaceuticals	Filing · EDGAR
May 20, 2016	Form 4	Cytokinetics CYTK	Filing · EDGAR
May 19, 2016	Form 4	Xenoport	Filing · EDGAR
Apr 7, 2016	Form 4	Apricus Biosciences	Filing · EDGAR
Jan 6, 2016	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jan 5, 2016	Form 4	Apricus Biosciences	Filing · EDGAR
Jun 24, 2015	Form 4	Ocera Therapeutics	Filing · EDGAR
Jun 22, 2015	Form 4	Ocera Therapeutics	Filing · EDGAR
Jun 15, 2015	Form 4	Concert Pharmaceuticals	Filing · EDGAR
Jun 11, 2015	Form 4	Anacor Pharmaceuticals	Filing · EDGAR
May 21, 2015	Form 4	Xenoport	Filing · EDGAR
May 21, 2015	Form 4	Cytokinetics CYTK	Filing · EDGAR
May 12, 2015	Form 4	Xenoport	Filing · EDGAR
Jan 26, 2015	Form 4	Apricus Biosciences	Filing · EDGAR
Jan 5, 2015	Form 4	Cytokinetics CYTK	Filing · EDGAR
Oct 24, 2014	Form 4	Apricus Biosciences	Filing · EDGAR
Sep 12, 2014	Form 4	Anacor Pharmaceuticals	Filing · EDGAR
Sep 12, 2014	Form 3	Anacor Pharmaceuticals	Filing · EDGAR
Jun 17, 2014	Form 4	Xenoport	Filing · EDGAR
Jun 13, 2014	Form 4	Ocera Therapeutics	Filing · EDGAR
Jun 11, 2014	Form 4	Xenoport	Filing · EDGAR
May 27, 2014	Form 4	Xenoport	Filing · EDGAR
May 22, 2014	Form 4	Cytokinetics CYTK	Filing · EDGAR
May 16, 2014	Form 4	Xenoport	Filing · EDGAR
Mar 17, 2014	Form 4	Concert Pharmaceuticals	Filing · EDGAR
Mar 17, 2014	Form 3	Concert Pharmaceuticals	Filing · EDGAR
Mar 11, 2014	Form 4	Apricus Biosciences	Filing · EDGAR
Mar 11, 2014	Form 3	Apricus Biosciences	Filing · EDGAR
Jan 6, 2014	Form 4	Santarus	Filing · EDGAR
Jan 3, 2014	Form 4	Cytokinetics CYTK	Filing · EDGAR
Dec 23, 2013	Form 4	Ocera Therapeutics	Filing · EDGAR
Dec 23, 2013	Form 3	Ocera Therapeutics	Filing · EDGAR
Oct 3, 2013	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
May 29, 2013	Form 4	Cytokinetics CYTK	Filing · EDGAR
May 16, 2013	Form 4	Xenoport	Filing · EDGAR
Apr 1, 2013	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Mar 12, 2013	Form 4	Santarus	Filing · EDGAR
Feb 5, 2013	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Nov 2, 2012	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Aug 28, 2012	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Aug 3, 2012	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Jul 27, 2012	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
May 24, 2012	Form 4	Cytokinetics CYTK	Filing · EDGAR
May 17, 2012	Form 4	Xenoport	Filing · EDGAR
May 3, 2012	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Apr 3, 2012	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Mar 13, 2012	Form 4	Santarus	Filing · EDGAR
Feb 3, 2012	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Nov 2, 2011	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Aug 1, 2011	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Jul 18, 2011	Form 4	Santarus	Filing · EDGAR
Jun 20, 2011	Form 3	Santarus	Filing · EDGAR
May 19, 2011	Form 4	Cytokinetics CYTK	Filing · EDGAR
May 12, 2011	Form 4	Xenoport	Filing · EDGAR
May 2, 2011	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Apr 4, 2011	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Feb 10, 2011	Form 4	Cytokinetics CYTK	Filing · EDGAR
Feb 10, 2011	Form 3	Cytokinetics CYTK	Filing · EDGAR
May 28, 2010	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
May 12, 2010	Form 4	Xenoport	Filing · EDGAR
Apr 2, 2010	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
May 8, 2009	Form 4	Xenoport	Filing · EDGAR
Apr 2, 2009	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Dec 17, 2008	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Aug 27, 2008	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Aug 21, 2008	Form 4	Xenoport	Filing · EDGAR
May 9, 2008	Form 4	Xenoport	Filing · EDGAR
Dec 14, 2007	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Dec 6, 2007	Form 4	Xenoport	Filing · EDGAR
Aug 30, 2007	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Jun 1, 2007	Form 4	Xenoport	Filing · EDGAR
May 18, 2007	Form 4	Xenoport	Filing · EDGAR
Feb 23, 2007	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Dec 19, 2006	Form 4	Xenoport	Filing · EDGAR
Dec 14, 2006	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Dec 8, 2006	Form 4	Xenoport	Filing · EDGAR
Nov 6, 2006	Form 4	Xenoport	Filing · EDGAR
May 4, 2006	Form 4	Xenoport	Filing · EDGAR
Jan 23, 2006	Form 4	Neurocrine Biosciences	Filing · EDGAR
Dec 14, 2005	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Jun 6, 2005	Form 4	Xenoport	Filing · EDGAR
May 31, 2005	Form 3	Xenoport	Filing · EDGAR
Feb 22, 2005	Form 4	Neurocrine Biosciences	Filing · EDGAR
Dec 14, 2004	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
May 28, 2004	Form 4	Neurocrine Biosciences	Filing · EDGAR
Mar 24, 2004	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Dec 16, 2003	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Nov 5, 2003	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Nov 4, 2003	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Oct 14, 2003	Form 4	Neurocrine Biosciences	Filing · EDGAR
Sep 3, 2003	Form 4	Neurocrine Biosciences	Filing · EDGAR
Sep 3, 2003	Form 3	Neurocrine Biosciences	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 4:47 PM ET. The filing on SEC.gov is the record.